Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

BACKGROUND: Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatm...

詳細記述

保存先:
書誌詳細
出版年:Respir Res
主要な著者: Marra, Alberto M., Halank, Michael, Benjamin, Nicola, Bossone, Eduardo, Cittadini, Antonio, Eichstaedt, Christina A., Egenlauf, Benjamin, Harutyunova, Satenik, Fischer, Christine, Gall, Henning, Ghofrani, Hossein Ardeschir, Hoeper, Marius M., Lange, Tobias J., Olsson, Karen M., Klose, Hans, Grünig, Ekkehard
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2018
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6299931/
https://ncbi.nlm.nih.gov/pubmed/30567595
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-018-0957-y
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料